Doctors’ social functions
have been replaced by templates and algorithms, leaving patients sidelined and
overtreated, one of the architects of a new movement to put patients at the
centre of evidence based medicine has said.
Clinical care has become “medicalised
and bureaucratised,” said
Trish Greenhalgh at the launch of the Campaign for Real EBM on 3 July at a
conference organised by BioMed Central on health services research. Greenhalgh
is professor of primary healthcare and dean for research impact at Queen Mary College,
University of London.
Greenhalgh acknowledged the “huge importance”
of evidence based
guidelines. Incentivising GPs to identify and treat undiagnosed hypertension
through the NHS’s Quality and Outcomes Framework (QOF) for primary care had
served to prevent countless strokes[1],
she said. “But add 150 more [targets] and you have taken that really good idea
and killed the reactive care,” she said.
In a recent paper in The
BMJ Greenhalgh
and colleagues set out the background to the campaign and described what had
gone wrong with evidence based medicine.1 Problems
included the misappropriation of the “evidence
based kitemark” by people with conflicts of interest; the ever increasing and
unmanageable volumes of evidence; the patient’s voice going unheard because of
the “managerialisation” of medicine; and the poor fit of guidelines with the
growing number of people with multi-morbidity.
The paper described one case of a “74
year old who is put on a
high dose statin because the clinician applies a fragment of a guideline
uncritically and who, as a result, develops muscle pains that interfere with
her hobbies and ability to exercise.” This was, the authors said, “a good
example of the evidence based tail wagging the clinical dog. In such scenarios,
the focus of clinical care shifts insidiously from the patient (this 74 year
old woman) to the population subgroup (women aged 70 to 75) and from ends (what
is the goal of investigation or treatment in this patient?) to means (how can
we ensure that everyone in a defined denominator population is taking
statins?).”
They said the case illustrated how “evidence
based medicine has
drifted in recent years from investigating and managing established disease to
detecting and intervening in non-diseases. Risk assessment using ‘evidence
based’ scores and algorithms (for heart disease, diabetes, cancer, and
osteoporosis, for example) now occurs on an industrial scale, with scant
attention to the opportunity costs or unintended human and financial
consequences.”
At the campaign launch Greenhalgh said,
“If patients knew how
much of their consultation was driven by box ticking they would be hopping mad.
We need more research about how to make the doctor listen to the patient. That needs to be the highest priority.” She
added that an estimated 60% of consultation time was spent box ticking.
QOF should be scaled back “massively,”
she said, although she
admitted that it would be difficult to decide how that would happen.
Greenhalgh said, “Currently,
when someone visits their GP or a
hospital doctor, quite a bit of the
encounter will typically be taken up by the doctor working through a structured
computer template that directs the questions to be asked, the parts of the body
to be examined, and the recommended medication. In the future, we want to
be in a situation where doctor and patient collaboratively set the agenda and
share decision making in a more emergent way, guided and supported by tools
that both reflect best research evidence—how the average patient is likely to
respond to the different treatment options—and also prompt discussion about
what matters to this patient.”
She believed that applying evidence based
medicine that mattered
to patients would save money. “There are lots of interventions that could or
might be effective but which people do not want,” she said.
Notes
Cite
this as: BMJ 2014;349:g4443
References
- ↵
Greenhalgh
T, Howick J, Maskrey N, for the Evidence Based Medicine
Renaissance Group. Evidence based medicine: a movement in
crisis? BMJ2014;348:g3725.
FREE Full
Text
[1] The
tragedy is that the 3 times more common myocardial infarction (heart attack)
risk is not reduced, and the endpoint of death is increased, as well as a major
reduction in quality of life including cognitive function, and the consumption
of the health-care funds which entails even greater harm. Moreover, the benefits
as to reduction of
stroke when measured in the number of patient needed to treat for one year for
the patient population which falls within the recently lowered guidelines is
over 300 patients. Moreover typical
treatment consists of a cocktail of 3 different categories of drugs. These
dismal results are derived from pharma’s clinical trials which are marketing
biased. By Ms. Greenhalgh pro-drug comments,
she is one of pharma’s opinion leaders. The
total lack of indication of the
fundamental problem with guidelines (go to http://healthfully.org/rep/id2.html
for a JAMA article on junk science used by pharma’s opinion leaders to justify
guidelines) confirms Dr. Kmietowicz is pro-pharma.